ipm- final

Indian Pharmaceutical Market - An Overview

JUN '07 MAT JUN '08 MAT JUN '09 MAT JUN '10 MAT0

5000100001500020000250003000035000400004500050000

3534 4015 37747193

2884132856

36630

43823

Incr. Value ( Rs. Cr.) Value ( Rs. Cr.)

IPM is growing at 19.6%, which is the highest growth since 4 years, with a

CAGR of 15.2%

Total IPM & Incremental Value (in Rs. Cr.) YoY

Val.

(Rs.

Cr.)

1

2

Growth Drivers of IPM

Macroeconomic Environment – Strong GDP growth, Rapid urbanization, Govt. initiatives, changing demographics & development of biologics.

Healthy Environment – Increase private & govt. spending & increase access to lower class towns.

Robust Market Trend – We observe that IPM is on a high growth trend for the past year after a relatively low profile in 2008-09.

3

Chart 4- Growth Drivers Of the IPM

Jun '08 MAT Jun '09 MAT Jun '10 MAT0

5

10

15

20

25

53

1211

1

8

7

7

Vol. Growth% Price-led Growth% NI Growth%

(14)

(11)

(20)

Figures in () indicate value growth of IPM in %

% g

row

th

4

Table 1: Performance of NI over the last 4 years

Jun '07 MAT Jun '08 MAT Jun '09 MAT Jun '10 MAT

Value of IPM (`Cr.) 28,841 32,856 36,630 43,823

No. Of NI 4,810 4,285 4,365 4,562

Value of NI (Cr.) 2,166 2,183 2,438 2,719

Contribution to IPM (%) 7.5 6.6 6.7 6.2

5


28,84132,856

36,630

43,823

Value of IPM (Cr.)


4,810

4,2854,365

4,562

No. Of NI

Jun '07 MAT

Jun '08 MAT

Jun '09 MAT

Jun '10 MAT

2,166 2,1832,438

2,719

Value of NI (Cr.)


7.56.6 6.7

6.2

Contribution to IPM (%)Contribution to IPM (%)

Performance of NI over the last 4 years

6

Jun ‘07 MAT Jun ’08 MAT Jun ’09 MAT Jun ’10 MAT

No. of NIs above Rs. 10 Cr. 10 10 15 20

Value of NIs above Rs. 10 Cr. 135 165 300 438

Contribution of NIs above Rs. 10 Cr. to total NI value 6.2% 7.5% 12.3% 16.1%

Value of largest NIs (Rs. Cr.) 23.3 30.9 52.1 81.4

Table 2: No of NIs above Rs. 10 Cr.

7

Top 10 New Introductions as per ‘JUN 10 MATS. No. Brand Company Sub-group Prod. Launch

YYYY-MMVal

( Rs. Cr.)IPM 2718.9

1 AEROCORT* CIPLA R03CK SALBUTAMOL + BECLOMETHASONE 2008 - 08 81.4

2 A TO Z NS* ALKEM A11A4 OTH. MULTIVIT.-MIN. SOLID 2008 - 11 28.5

3 JANUMET MSD A10BT ANTIDAIBETICS COMBINATIONS (METFORMIN +SITAGLIPTIN)

2008 - 12 27.8

4 MTP KIT CIPLA G03K1 MIFEPRISTON 2009 - 02 26.3

5 GALVUS NOVARTIS A10BE OTHER ANTIDIABETICS-PLAIN (VILDAGLIPTIN)

2008 - 08 26.3

6 MTPROST KIT CIPLA G03K1 MIFEPRISTON 2009 - 02 26.2

7 POLYBION SF* MERCK A11E8 OTH. B-COMP.COMBINATION LIQIUDS

2009 - 06 25.1

8 POLYBION-LC* MERCK A11E8 OTH. B-COMP.COMBINATION LIQIUDS

2009 - 03 20.9

9 NORFLOX-TZ* CIPLA P01A6 TINI+ OTH. COMBINATION SOLID 2008 - 12 20.5

10 JALRA USV A10BE OTHER ANTIDIABETICS-PLAIN (VILDAGLIPTIN)

2009 - 01 19.9

* REFORMULATIONS

8

Insights Among products that were launched New packs/ Reformulations

showed the highest gain. New Introduction by Cipla constituted to 51% amongst top ten

Brands. Demonstrating their success in brand building. Antidiabetics form the major therapy amongst new Introduction,

indicating a strong potential in the segment. Among the top 10 companies in IPM, only Cipla & Alkem are

reflected in top 10 new introductions. 6/10 NI are combinations, thus indicating continued focus on

combination drugs in India Mifepriston brands together account for Rs. 50 Cr. within a year of

launch, thus indicating the huge potential of the contraceptive market

9

Rank (G/L over last year

Brand

Company

Value

(Rs. Cr.)

Incr. Value (Rs. Cr.)

Value Growth %

Jun' 09 MAT Jun'10 MAT

IPM 43,823 7,193 11 20

1(1) Corex Pfizer 204 32 17 19

2(-1) Phensedyl Piramal Healthcare 203 24 17 19

3(0) Voveran Novartis 159 24 6 18

4(3) Augmentin GSK 158 38 10 31

5(0) Human Mixtard 30/70 Abbott 157 32 3 26

6(7) Revital Ranbaxy 152 47 29 45

7(4) Becosules Pfizer 140 30 15 27

8(1) Dexorange Franco Indian 140 26 16 22

9(-1) Zifi FDC 138 23 8 20

10(2) Monocef Aristo Pharma 136 26 24 24

Top 10 brands (Jun’ 10 MAT)

10

INSIGHTS Cipla despite being the no. 1 company does not have a single brand in Top 10 products.

Except for Human Mixtard 30/70 (Abbott)- used for Chronic Therapy, Acute therapy still has a strong foothold in the Top 10 brands.

Corex (204Cr.) & Phensedyl (203Cr.), both cough syrups occupying No.1 & 2 position respectively, are going neck to neck.

Zifi (FDC) & Monocef (Aristo), No.9 & 10 brands respectively, belong to the same class - Cephalosporins.

Zifi with a value growth of 20% in Jun’ 10 MAT compared to 8% in Jun’09 MAT shows positive signs for Sub-class- Cefixime.

Augmentin (GSK) shows the 2nd highest incremental value of Rs.38Cr. even after 30 years of its launch.

11

80 81 81 81

20 19 19 19

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%


MNC's

Indian Companies

Contribution of Indian Companies & MNC’s to IPM

28,841 32,856 36,630 43,823

% c

ontr

ibuti

on

12

INSIGHTS

With MNC’s looking out for Inorganic growth in IPM, the figures are bound to improve for MNC’s in near future.(e.g. Abbott-Piramal)

13

Growth drivers ofIndian Cos.

VsMNCs

14

Jun'08 MAT

Jun'09 MAT

Jun'10 MAT

0

2

4

6

8

10

12

14

16

18

20

52

111

1

09

9

8

Vol growth % Price led growth %NI Growth %

% G

row

th

Jun'08 MAT

Jun'09 MAT

Jun'10 MAT

0

5

10

15

20

25

5 4

152

1

1

5

3

5

Vol Growth %Price led Growth %NI Growth %

% G

row

th

INDIAN COS. MNC

15

Top 10 companies in the IPM

16

Rank(Jan’10 MAT)

Companies Val(Rs. Cr.)

MS (%)

G/L in MS over last year

Incr. value(Rs. Cr.)

Val growth(%)

1. Cipla 2,311 5.3 -0.04 365 19

2. Ranbaxy 2,104 4.8 -0.2 273 15

3. GSK 1,872 4.3 -0.03 295 19

4. Piramal Healthcare

1,835 4.2 -0.03 288 19

5. Zydus Cadila

1,641 3.7 0.1 319 24

6. Sun Pharma

1,625 3.7 0.2 345 27

7. Alkem 1,413 3.2 0.1 258 22

8. Pfizer 1,370 3.1 0.1 245 22

9. Mankind 1,298 3.0 0.3 340 35

10. Abbott 1,243 2.8 0.1 239 24

Top 10 companies in the IPM

17

Growth Drivers of Top companies

Cipla Ranbaxy GSK Piramal Healthcare

Zydus Cadila

Sun Pharma

Alkem Pfizer Mankind Abbott-5

0

5

10

15

20

25

30

35

40

611

17

5

18 16 18 1724

201

-1

1

4

-5

3

-1

3

12 5

1

13

67 9 2

13

1

NI Growth % Price Led Growth % Volume Growth %

(19) (22)(22)(27)

(24)(19)(19)(15)

(24)

(35)

% G

row

th


18

Company Turnover & Growth GridValue Growth (%) Turnover > Rs. 250 Cr. Turnover Rs. 100 - Rs. 250 cr. Turnover Rs.60–

Rs.100Cr.High>20%

Elder Pharma, Mankind, Macleods, Intas, Sun Pharma, MSD, Unichem, Zydus Cadila,

Abbott, Sanofi Aventis, Microlabs, USV, Alkem, DRL, Franco Indian,

Indoco, Pfizer, Merck Ltd, Alembic, Glenmark, Novartis

Hegde & Hegde, Geno, Meyer Organics, Win Medicare, Eli

Lilly, Allergan, Wanbury, Systopic, Orchid Chem &

Pharma, Centaur, Blue Cross, Hetero Healthcare

Troikaa Pharma, Tablets India, Baidyanath, East India, UCB Pharma, TTK

Healthcare Ltd.

Val. Contri.(%) to IPM 42% 4% 1%Medium10-20%

Cipla, GlaxoSmithKline, Piramal Healthcare, Ipca labs, Aristo Pharma, Lupin Ltd., Torrent Pharma, AstraZeneca, FDC,

Ranbaxy, Wockhardt, Emcure, Cadila Pharma

Medley, Apex, Unique Pharma, Janssen Cilag, Jagson

Pal, Wallace, Maneesh Pharma, Fourts India,

Biochem, Raptakos Brett, Modi Mundi Pharma,

Bestochem, Ajanta Pharma, Charak Pharma, Panacea

Biotech, Albert David

Serum Institute, British Biological, Serdia, Walter

Bushnell, Pharmed, Natco Pharma,

Universal, Johnson & Johnson, Anglo French

Drugs

Val. Contri.(%) to IPM 34% 6% 2%Low

<10%Himalaya Drug Shreya Lifescience, CFL,

Dabur, Ind-SwiftBiological E, Bayer Pharma Ltd., Dey S,

Paras, RPG Life SciencesVal. Contri.(%) to IPM 1% 1% 1%

Companies that have moved up the grid, Companies that have moved down the grid, New companies that have entered the grid, Companies that have remained in the same grid

19

ACUTE SEGMENT GROWTH DRIVERS

Jun'08 MAT Jun'09 MAT Jun'10 MAT0

2

4

6

8

10

12

14

16

18

20

3 2

11

88

8

NI growth%Price led growth %Volume led growth%

(12)(11)

(19)

% g

row

th


20

CHRONIC SEGMENT GROWTH DRIVERS

Jun'08 MAT Jun'09 MAT Jun'10 MAT0

5

10

15

20

25

11

6

15

2

2

17

7

7

NI growth%Price led growth %Volume led growth%

% g

row

th

(23)

(14)

(20)


21

Table 7:Top 10 Therapy segments in the

IPM

22

Rank (G/L over last

year)

Therapy

Val. Contri. % Val. Gr. %

No. of NIs

Val/NI (Rs. Cr)

CAGR* (%)

JUN’09 MAT

JUN’10 MAT

JUN’09 MAT

JUN’10 MAT

IPM 36,631(Rs.Cr)

43,823 (Rs.Cr)

11 20 4,562 0.6 15

1 Anti Infectives 17.5 17 9 16 705 0.64 14

2 Cardiac 11.3 11.4 14 21 354 0.54 19

3 Gastro Intestinal 10.9 10.9 11 20 555 0.37 14

4 Respiratory 8.9 8.9 11 20 430 0.65 14

5 Pain/Analgesics 8.7 8.6 10 19 568 0.51 12

6 Vitamins/ Minerals/ Nutrients 7.7 7.8 8 21 361 0.95 12

7 Gynaecology 5.8 5.8 14 20 287 0.71 17

8(+2) Anti Diabetic 5.3 5.7 15 29 116 1.51 23

9 Neuro/CNS 5.5 5.6 13 22 230 0.47 17

10(-2) Derma 5.5 5.5 15 19 337 0.5 15

*Note: CAGR is drawn over a period of 4 years

23

INSIGHTS

Anti Diabetic segment is the fastest growing and most promising segment and most important growth driver for IPM.

All chronic therapies (>20%) are contributors while most acute therapies (<20%) are dilutors to the growth of IPM.

There is high emphasis on New Introductions which is a key to growth of IPM with the average value/NI increasing for most therapies.

24

Chart 10: Growth drivers of Top 10

Therapy segments in the IPM

25

Chart10:Growth drivers of Top 10 Therapy segments in IPM

IPM

Anti Infecti

ves

Cardiac

Gastro In

testinal

Respira

tory

Pain/Analgesic

s

Vitamins/M

inerals/Nutri

ents

Gynaecology

Anti Diabetic

Neuro/C

NS

Derma

-5

0

5

10

15

20

25

30

35

12 1217

139 8 7 8

18 1510

1

-3

22 2 2 3

22

1

7 75

58 9 12 9

9

5

8

Vol.Growth% Price led Growth% NI Growth%

% G

row

th

(16)(21) (21)

(19)(22)

(20)(20) (20)

(29)

(20) (19)


26

INSIGHTS

Anti Diabetic and Cardiac segments have shown tremendous volume growth which reflects the potential of chronic therapy in today’s market.

Anti Infective segment has shown negative price led growth due to price reduction which is indicative of high competition in this segment.

IPM is driven by volume and NI growth rather than price led growth which is indicative of a healthy industry and good future prospects.

27

Anti-infectives Therapy

28

Company Val.(Rs. Cr.)

Mkt. Share

(%)

Val. Gr.

(%)

Brands > Rs. 10 Cr. Top Brand Value of Top

Brand (Rs. Cr.)No. Value

(Rs. Cr.)

Contri. To

Portfolio (%)

Anti-infectives 7,467 100 16 160 4,772 64 AUGMENTIN 158

RANBAXY (1) 760 10.2 13 16 650 85 MOX 126

ALKEM (2) 715 9.6 15 15 571 80 TAXIM 133

ARISTO PHARMA (3) 503 6.7 22 7 422 84 MONOCEF 136

CIPLA (4) 464 6.2 19 10 316 68 NOVAMOX 85

GLAXOSMITHKLINE (5) 416 5.6 23 6 391 94 AUGMENTIN 158

Top 5 companies in the Anti-infectives Therapy MarketFigures in ( ) indicate rank as per Jun ‘ 09 MAT

• Augmentin (GSK) being the top brand in the Anti-infectives segment, Ranbaxy still holds No.1 position.• Value growth of GSK has been the highest at 23%.

29

760

715503

464

416

Ranbaxy (1)Alkem (2)Aristo pharma (3)Cipla (4)GSK (5)

(10.2 %)

(9.6%)

(6.7%)

(6.2%)

(5.6%)

Value (Rs. Cr.)of Top 5 Companies in the Anti-infectives Therapy Market

Rank as per Jun ‘ 09 MAT

Anti-infectives Val. (Rs. Cr.) = 7,467Figures in ( ) indicate Market Share (%)

30

Cardiac Therapy

31

CompanyVal(Rs. Cr)

MrktShare(%)

ValGr.

(%)

Brands > Rs. 10 Cr

Top Brand

Value ofTop

Brand(Rs. Cr)

No.Value

(Rs. Cr)

Contri to Portfolio

(%)

CARDIAC 5006 100 21 123 2769 55 STORVAS 97

Sun Pharma (2) 329 6.6 27 11 213 65 AZTOR 39

Torrent Pharma (1) 317 6.3 18 9 191 60 DILZEM 47

Zydus Cadila (3) 301 6.0 22 6 212 70 ATEN 82

Unichem (6) 286 5.7 28 6 181 63 LOSAR-H 63

Cipla (4) 275 5.5 17 6 147 53 AMLOPRES 44

Top 5 Companies in the Cardiac Therapy Market

Figures in ( ) indicate rank as per Jun ’09 MAT

32

Insights0 Storvas is the top brand in Cardiac segment but Ranbaxy

does not feature in top 5 companies.0 Sun Pharma, with a bigger product basket (11 Brands)

leads the market.0 Storvas and Aztor both are among the top brands thus

indicating good acceptance of dyslipidaemics in the market.

0 With Dilzem, Aten and Amlopres featuring in top 5 brands, is indicative of good anti anginal therapy market.

0 The top 3 companies have managed to remain in the top positions since last year.

0 Unichem has shown a high growth rate and has moved up to number 4.

33

Gastro Intestinal Therapy

34

CompanyValue(Rs. Cr.)

Mkt Share

(%)

Value Growth

(%)No.

Brands>10 Cr

Top Brand

Value of Top Brand(Rs. Cr.)

Value (Rs. Cr.)

Contri. to portfolio

(%)

Gastro Intestinal 4771 100 20 103 2687 56 Zinetac 99

ABBOTT (1) 291 6.1 18 9 265 91 Digene 92

ZYDUS CADILA (2) 265 5.6 24 7 194 73 Ocid 52

DRL (3) 231 4.8 23 6 193 84 Omez 92

ALKEM (5) 213 4.5 38 5 158 74 Pan 59

MANKIND (6) 198 4.1 29 3 62 31Zenflox-

OZ28

Top 5 companies in the Gastro Intestinal Therapy Market


35

Insights

0 Zinetac is the top brand in GI segment but GSK does not feature in top 5

0 Mankind with just 3 brands greater than 10 crores has made it top 5

0 Ocid, Omez and Pan are among the top brand thus indicating good acceptance of PPI in the market.

0 Abbott has 91% brands above 10 crores, possibly the reason why it is placed at the top in GI category

0 The top 3 companies have managed to maintain their positions since last year

0 Alkem has shown a high growth rate and has moved up a spot to number 4

36

Respiratory therapy Market

37

Table 11: Top 5 Companies in Respiratory Therapy Market

Company Value (Rs cr.)

Mkt Share

(%)

Val. Growth

(%)Brands > Rs10 cr Top Brand

Value of top brand

(Rs. Cr.)

No. Value (Rs. Cr)

Contribution to portfolio(%)

Respiratory 3895 100 20 72 2258 58 Corex 204

Cipla 715 18.4 16 13 553 77 Asthalin 126

Piramal 311 8 15 4 277 89 Phenesedyl Cough 203

Pfizer 249 6.4 23 2 223 89 Corex 204Zydus Cadila 173 4.4 23 3 102 59 Deriphylline 62

GSK 168 4.3 9 6 115 69 Cetzine 41

38

INSIGHTS

0 Companies having a Value growth of more than 20 % are the growth drivers of respiratory segment.

0 Pfizer and Zydus Cadila are the growth drivers among top 5 companies.

0 Pfizer and Piramal Healthcare are highly vulnerable because of their high dependence on one brand in their portfolio (89%)

0 Top 5 companies in Respiratory segment contribute to 40% of market.

39

Anti-Diabetic Therapy Market

40

Company Value (Rs. Cr.)

Market Share

(%)Growth

(%) No.

Brands > Rs. 10 crore

Top brandValue of

Top Brand (Rs. Cr.)

Value (Rs. Cr.)

Contri. To portfolio

(%)

Anti Diabetic 2500 100 29 63 1614 65 Human Mixtard 30/70 157

Abbott (1) 442 17.7 20 10 393 89 Human Mixtard 30/70 157

USV (2) 272 10.9 30 9 231 85 Glycomet 66

Sanofi Aventis (3) 199 7.9 31 5 184 93 Lantus 68

Sun Pharma (4) 175 7 28 6 138 79 Glucored 45

Eli Lilly (5) 113 4.5 23 3 85 76 Huminsulin 30/70 63


Top 5 companies in the Anti-diabetic Therapy Market

41

Top companies in Each Zone

42

TOP COMPANIES IN EACH ZONESRANK IPM NORTH EAST WEST SOUTH

1 CIPLA CIPLA ALKEM CIPLA RANBAXY

2 RANBAXY RANBAXY GSK PIRAMAL (1) CIPLA

3 GSK PIRAMAL PIRAMAL (1) ZYDUS (2) SUN

4 PIRAMAL GSK RANBAXY(-1) GSK (-2) GSK

5 ZYDUS MANKIND SUN PFIZER (2) ZYDUS

6 SUN ZYDUS ZYDUS (1) RANBAXY (-2) ABBOTT (1)

7 ALKEM LUPIN CIPLA (-1) EMCURE (-1) PIRAMAL (-1)

8 PFIZER PFIZER ALEMBIC (2) SUN (1) DRL (1)

9 MANKIND (2) ALKEM (2) ARISTO FDC (-1) MICROLABS (-1)

10 ABBOTT SUN PFIZER (-2) MANKIND (3) PFIZER

43

INSIGHTS

0 Market leader Cipla is doing well in most markets except east

0 Similarly Ranbaxy is doing well in most markets except west, and Piramal in south

0 Companies such as Microlabs and Dr Reddy’s laboratories have a grip on south market only, and are not in top ten in other markets.

44

Top 10 co. across town classes

45

Rank Metro Class I Class II-VI Rural1 Ranbaxy Cipla Cipla Cipla

2 Cipla RanbaxyPiramal

HealthcarePiramal

Healthcare3 Sun Pharma GSK GSK GSK

4 Zydus CadilaPiramal

HealthcareRanbaxy Mankind

5 Pfizer Zydus Cadila Mankind Ranbaxy 6 GSK Sun Pharma Alkem Alkem

7Piramal

HealthcareAlkem Zydus Cadila Zydus Cadila

8 Sanofi Aventis Lupin Sun Pharma Aristo Pharma9 Abbott Pfizer Aristo Pharma Pfizer

10 Lupin Abbott Pfizer Abbott

Top 10 companies across Companies

GSK has a stronger hold in Class I-IV & Rural areas than in Metro Pfizer & Abbott trying to penetrate the class I-IV & Rural market Growing presence of MNCs can be seen in rural areas

46

Hospital Segment Performance

47

Jun '07 MAT Jun '08 MAT Jun '09 MAT Jun '10 MAT0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

93 93 92 91

7 7 8 9

HAS SSA

% C

on

trib

uti

on

(14) (11) (20)

(16) (12) (21) (37)

Rs. 31,173 Cr. Rs. 35,464 Cr. Rs. 39,786 Cr.

Rs. 48,136 Cr.

(14)

Contribution of SSA and HSA in the IPMFigures in ( ) are value growth %

48

Hospital Segment Performance

0 Hospital segment has registered a robust value growth of 37% (Jun 10 MAT) as compared to last year’s 21% (Jun 09 MAT).

0 Hospital segment contributed 9% to the total IPM (SSA + HAS) as per Jun’10 MAT.

0 The trend for past 4 years showed an upward trend in this contribution from Jun’07 MAT to Jun’10 MAT, which supports the fact that Hospital sector is gaining importance in the IPM and as a result more players are strengthening their focus towards this sector.

0 In terms of growth, Hospital sales showed high growth of 37% growth as per Jun’10 MAT

49

Top Companies in Hospital Market

HSA rank Jun ‘10 MAT (HSA rank Jun ‘07 MAT)

Company Value ( Rs. Cr.)

Val Gr. ( %)

IPM 4,313 37

1 (1) GlaxoSmithKline 251 35

2 (6) Sun Pharma 240 60

3 (2) Cipla 228 44

4 (5) Zydus Cadila 189 39

5 (3) Pfizer 189 57

6 (9) Piramal Healthcare 180 44

7 (4) Sanofi Aventis 178 48

8 (8) Ranbaxy 165 46

9 (10) Lupin Limited 156 39

10 (7) Alkem 137 16

50

Insights

0 There is a considerable shift in the ranks of companies in the hospital segment

0 Sun pharma, Sanofi Aventis and Alkem has the greatest had the greatest change in the ranking.

51

RankTherapy

Value contribution(%) Value growth (%)CAGR (%)(G/L) over

last year)June ‘09

MATJune ‘10

MATJune ‘09

MATJune ‘10

MAT

IPM 3155 Crs 4313 Crs 21 37 23

1 Anti infectives 26.8% 25.6% 18 30 20

2 Cardiac 11.11% 11.8% 19 45 25

3 Gastro intestinal

8.3% 8.1% 21 34 19

4 Pain/Analgesics

7.4% 7.2% 21 33 22

5 Gynaec 6.0% 5.9% 26 34 21

6 Respiratory 5.9% 5.6% 38 30 29

7(+1) Neuro/CNS 5.0% 5.4% 29 49 31

8 (-1) Vitamins/Minerals/Nutrients

5.1% 5.0% 18 32 18

9 Others 4.3% 4.9% 11 57 31

10 Anti diabetic 3.5% 4.1% 21 58 35

Top therapies in hospital market

52

Insights

0 All the top 10 therapies have recorded a robust double digit growth i.e. more than 30% growth.

0 Neuro and CNS increased the contribution by 0.4%0 New introductions added an incremental value of Rs.

300 Cr. which constitutes 26% of the total incremental value.

53

Specialty Rx contribution%

Jun ‘ 09 MAT Jun ‘10 MAT

All Specialties 156 crs 164 crs

General practitioners

40.2% 40.1%

Mass specialties 28.6 % 28.6%

Super specialties 31.1% 31.3%

Specialty – wise prescription split

54

General p

racti

tioners

Mass sp

ecialit

ies

Super specia

lities

0

10

20

30

40

50

60

70

62.712

44.61648.516

65.764

46.90451.332

Jun '09 MATJun'10 MAT

All specialties

Rx contri-bution

Highest Rx contribution was obtained from general practitioners . In Jun’10 general practitioners added more number of prescriptions (3.1cr).

55

Therapies Rx contribution %

Total Rx (Rs. Cr.)

G.P.Total Super specialties

Mass specialties

Total 164 40% 31% 29%

Anti infective 63 50% 24% 26%

Cardiac 9 20% 42% 38%

Gastro intestinal 51 43% 26% 31%

Respiratory 37 49% 18% 33%

Pain/analgesics 61 40% 36% 25%

Vitamins / Minerals / Nutrients 30 38% 28% 35%

Gynecology 11 30% 12% 58%

Anti Diabetic 4 14% 42% 44%

Neuro / CNS 11 21% 53% 27%

Derma 9 34% 36% 30%

Top therapies in IPM

56

Anti infective

Pain / analgesics

Gastro intestinal

Respiratory

Vitamins/ Minerals / Nutrients

Gynaecology

Neuro / CNS

Derma

Cardiac

Anti Diabetic

0 10 20 30 40 50 60 70

63

61

51

37

31

11

11

9

9

4

Total Rx in cr.

Total Rx in cr.

Therapies

Currently , anti infective therapy is the growth driver of IPM

57

GPs - highest prescription contribution: Anti infective therapy

Super specialties - highest prescription contribution: neuro/CNS therapy

Mass specialties - highest prescription contribution: Gynaecology

Anti infective

Respiratory

Gastro intestinal

Pain / Analgesics

Vitamins / Minerals / Nutrients

Derma

Gynaecology

Neuro / CNS

Cardiac

Anti Diabetic

0% 10%20%30%40%50%60%70%

Mass specialties

Super specialties

G.P.

Rx contribution %

58

Rank CompaniesRx contribution (%)

Jun '09 MAT Jun '10 MAT

IPM 156 Cr. 164 Cr.

1 (1) GSK 10.8% 10.7%

2 (2) Cipla 10.1% 9.9%

3 (4) Mankind 8.1% 9.2%

4 (3) Piramal Healthcare 8.9% 8.8%

5 (5) Zydus Cadila 7.1% 7.1%

6 (6) Ranbaxy 7.0% 6.7%

7 (7) DRL 6.6% 6.6%

8 (8) FDC 6.1% 5.9%

9 (9) Alkem 5.3% 5.6%

10 (11) Sun Pharma 4.7% 4.9%

Figures in ( ) are value growth %

Top co. in IMS Rx Audit

Total IPM = 43823 Cr.

Total Rx IPM = 164 Cr.

Rx IPM contributes to 0.3% of total

IPM

Indicating a heavy trend of OTX selling in

India

59

Top co. in Prescription Audit

0 Rx IPM contributes to 0.3% of total IPM (Jun ‘10 MAT)

0 The total contribution of Rx to IPM is low. Indicating a heavy trend of OTX.

0 GSK & Cipla have managed to be doctor’s favorite while prescribing.

0 Mankind has grown by leaps and bound each year even in Rx market. Indicating good acceptance among doctors.

0 GSK is the only MNC that features among the top 10 (Assumption: Piramal & Ranbaxy started as Indian and later acquired by MNC)

Insights

60

June '10 MATRx contri (%) Rxber contribution (%)

Total 164 Cr. 244000GP Total 66 Cr. 94000GP (Non MBBS) 65% 69%GP (MBBS) 35% 32%MASS SPECIALITIES 47 Cr. 65000Gynaecologist 27% 34%CP 30% 28%Paediatrician 28% 23%Gen. Surgeon 14% 16%SUPER SPECIALITIES 51 Cr. 85000Dentist 29% 33%Orthopaedic 12% 12%Opthamologist 9% 11%ENT Specialist 8% 8%Cardiologist 6% 7%Dermatologist 6% 6%Chest TB Specialist 4% 5%Neurologist Neuro Surgeon 3% 5%Nephrologist Urologist 3% 4%Diabetologist Endocrinologist 3% 3%Psychiatrist 3% 3%Gastroenterologist 3% 3%Oncologist 1% 2%

Prescription & Prescriber Dispersion

61

Prescription & Prescriber Dispersion

Insights

0 Max. prescribers are GP (Non MBBS) – Might indicate patients price sensivity towards Doctor’s fees.

0 Top 3 Rxber contribution(1) GP (Non-MBBS) (2) Gynaecs (3) Dentists

0 Barring dentists the overall superspeciality size is comparitively smaller.

62

Indian Vaccine Market - An Overview

63

Total IPM & Incremental Value (in Rs. Cr.) YoY

Val. (

Rs.

Cr.

)

Indian Pharmaceutical Market - An Overview

Source: IMS – June’10 MAT

19.6% Gr ,highest since 4 years, CAGR- 15.2%

64

(>>) (-2)

(24)

(53)Va

l. (R

s. C

r.)

June MAT

Growth double

than last year

Vaccine Market - Trend

Source: IMS – June’10 MATFig ( ):% Val Gr

Vaccine Market:

Business Channels

65

(10)

(41)

(48)

(53)

(-27)(96)

(>>)

(19)


Dispensing doctors & Hospitals drive market

Vaccine Market:Indian Vs MNCs

66

(27)

(21) (38)

(64)


MNCs drive

market

Vaccine Market: Top 10 Companies

67

Rank June’10

MAT

Company Val.(Rs. Cr.)

Market Share %

Val. Growth %

Vaccine Market 726 100% 53

1 GSK 131 18% 23

2 Sanofi Aventis 129 18% >>

3 Pfizer 71 10% 75

4 Novartis 68 9% -12

5 Serum Institute 68 9% 40

6 Panacea Biotech 59 8% 57

7 VHB Lifesciences 33 5% >>

8 Zydus Cadila 32 4% 56

9 MSD 31 4% >>

10 Shantha Biotech 24 3% 15

Top 10 contributes

90%

Vaccine Market :Top Therapies

Therapies Value (Rs. Cr.)

Share % Val. Grwth % Incr. Val. (Rs. Cr.)

June’09 MAT

June’10 MAT

June’09 MAT

June’10 MAT

Vaccine Market

726.1 100% 24 53 93 250

Toddler Vaccine

211 29% 55 60 47 79

Adult Vaccine

205 28% -4 22 -7 37

Paediatric Combination Vaccines

146 20% 67 >> 28 77

Paediatric Single Vaccines

131 18% 25 32 20 32

All Other Vaccines

33 5% --- 431 6 2768

Vaccine Market: Top 10 Brands Rank

June’10 MAT

Brands Company Val.(Rs. Cr.)

Val. Growth % Incr. val. (Rs. Cr.)

June’09 Mat

June’10 MAT

June’09 Mat

June’10 MAT

Vaccine Market

726 24 53 93.1 250

1 Prevenar Pfizer 71 150 75 24 30

2 Rabipur Novartis 68 4 -12 3 -9

3 Pentaxim Sanofi Aventis

46 >> >> 7 39

4 Havrix GSK 37 9 47 2 12

5 Varivax VHB 33 59 >> 5 18

6 Vaxirab Zydus Cadila 32 -11 56 -3 11

7 Varil Rix GSK 25 -3 -9 -1 -2

8) Gardasil MSD 22 ---- >> 5 16

9 Verorab Sanofi Aventis

21 ---- ---- 0 21

10 Rotarix GSK 21 ---- >> 10 11

69

Top 10 contributes

--50%

Vaccine Market : Top 10 NIS

NIs Comapny Launch Date

YYYY MM

Value(Rs. Cr.)

Incr. Val.(Rs. Cr.)

Vaccine Market 104 79

Gardasil MSD 2008 10 22 16

Rotarix GSK 2008 07 21 11

Pentavac Serum Institute 2008 10 16 12

Cervarix GSK 2009 02 11 10

Polprotec Panacea Biotech 2008 07 9 6

Xprab RANBAXY 2009 10 7 7

Quadrovax Serum Institute 2008 11 4 3

Comvac- 5 Bharat Biotech 2009 02 3 3

Pentavac - SD Serum Institute 2009 11 2 2

Shan HIB- DPT Shantha Biotech

2008 09 2 170

NIs 7.55% contr,

ipm- final

Documents